Effects of nicotinic acid on gene expression: Potential mechanisms and implications for wanted and unwanted effects of the lipid-lowering drug

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 10, 2011, Pages 3048-3055

  Kang, Insug ^a   Kim, Sang Wook ^b   Youn, Jang H ^a,b  

^a Kyung Hee University Hospital   (South Korea)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACIPIMOX; CHOLESTEROL ESTER TRANSFER PROTEIN; CYTOKINE; DIACYLGLYCEROL ACYLTRANSFERASE 1; DIACYLGLYCEROL ACYLTRANSFERASE 2; FATTY ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MESSENGER RNA; NICOTINIC ACID; NICOTINIC ACID RECEPTOR; RECEPTOR; TRANSCRIPTION FACTOR FKHR; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FATTY ACID BLOOD LEVEL; GENE EXPRESSION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOLYSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TREATMENT RESPONSE;

ANIMALS; FATTY ACIDS, NONESTERIFIED; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION; HORMONES; HUMANS; HYPOLIPIDEMIC AGENTS; INSULIN RESISTANCE; LIPOLYSIS; NIACIN; RECEPTORS, NICOTINIC;

EID: 80053530578     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1104     Document Type: Review

References (78)

1. Bodor ET, Offermanns S 2008 Nicotinic acid: an old drug with a promising future. Br J Pharmacol 153(Suppl 1):S68-S75 (Pubitemid 351340990)
2. Karpe F, Frayn KN 2004 The nicotinic acid receptor - a new mechanism for an old drug. Lancet 363:1892-1894 (Pubitemid 38748647)
3. Carlson LA 2005 Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review. J Intern Med 258:94-114 (Pubitemid 41025967)
4. Kamanna VS, Kashyap ML 2008 Mechanism of action of niacin. Am J Cardiol 101:20B-26B
5. Walldius G, Wahlberg G 1985 Effects of nicotinic acid and its derivatives on lipid metabolism and other metabolic factors related to atherosclerosis. Adv Exp Med Biol 183:281-293
6. Alvarsson M, Grill V 1996 Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin responders. Scand J Clin Lab Invest 56:563-570 (Pubitemid 26342641)
7. Kelly JJ, Lawson JA, Campbell LV, Storlien LH, Jenkins AB, Whitworth JA, O'Sullivan AJ 2000 Effects of nicotinic acid on insulin sensitivity and blood pressure in healthy subjects. J Hum Hypertens 14:567-572
8. Poynten AM, Gan SK, Kriketos AD, O'Sullivan A, Kelly JJ, Ellis BA, Chisholm DJ, Campbell LV 2003 Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content. Metabolism 52:699-704 (Pubitemid 36896302)
9. Choi S, Yoon H, Oh KS, Oh YT, Kim YI, Kang I, Youn JH 2011 Widespread effects of nicotinic acid on gene expression in insulin-sensitive tissues: implications for unwanted effects of nicotinic acid treatment. Metabolism 60:134-144
10. Drood JM, Zimetbaum PJ, Frishman WH 1991 Nicotinic acid for the treatment of hyperlipoproteinemia. J Clin Pharmacol 31:641-650
11. Guyton JR, Capuzzi DM 1998 Treatment of hyperlipidemia with combined niacin-statin regimens. Am J Cardiol 82:82U-84U; discussion 85U-86U
12. Drexel H 2009 Statins, fibrates, nicotinic acid, cholesterol absorption inhibitors, anion-exchange resins, omega-3 fatty acids: which drugs for which patients? Fundam Clin Pharmacol 23:687-692
13. Semple G, Skinner PJ, Gharbaoui T, Shin YJ, Jung JK, Cherrier MC, Webb PJ, Tamura SY, Boatman PD, Sage CR, Schrader TO, Chen R, Colletti SL, Tata JR, Waters MG, Cheng K, Taggart AK, Cai TQ, Carballo-Jane E, Behan DP, Connolly DT, Richman JG 2008 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J Med Chem 51:5101-5108
14. Shen HC, Colletti SL 2009 Novel patent publications on high-affinity nicotinic acid receptor agonists. Expert Opin Ther Pat 19:957-967
15. Aktories K, Schultz G, Jakobs KH 1980 Regulation of adenylate cyclase activity in hamster adipocytes. Inhibition by prostaglandins, α-adrenergic agonists and nicotinic acid. Naunyn Schmiedebergs Arch Pharmacol 312:167-173 (Pubitemid 10123986)
16. Lorenzen A, Stannek C, Lang H, Andrianov V, Kalvinsh I, Schwabe U 2001 Characterization of a G protein-coupled receptor for nicotinic acid. Mol Pharmacol 59:349-357 (Pubitemid 32108569)
17. Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, Ohishi T, Hiyama H, Matsuo A, Matsushime H, Furuichi K 2003 Molecular identification of nicotinic acid receptor. Biochem Biophys Res Commun 303:364-369 (Pubitemid 36338250)
18. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, Pfeffer K, Offermanns S 2003 PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 9:352-355 (Pubitemid 36362793)
19. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, Eilert M, Ignar DM, Murdock PR, Steplewski K, Green A, Brown AJ, Dowell SJ, Szekeres PG, Hassall DG, Marshall FH, Wilson S, Pike NB 2003 Molecular identification of high and low affinity receptors for nicotinic acid. J Biol Chem 278:9869-9874 (Pubitemid 36800490)
20. Le Bloc'h J, Leray V, Chetiveaux M, Freuchet B, Magot T, Krempf M, Nguyen P, Ouguerram K 2010 Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs. J Pharmacol Exp Ther 334:583-589
21. Stone SJ, Myers HM, Watkins SM, Brown BE, Feingold KR, Elias PM, Farese Jr RV 2004 Lipopenia and skin barrier abnormalities in DGAT2-deficient mice. J Biol Chem 279:11767-11776 (Pubitemid 38401682)
22. Hernandez C, Molusky M, Li Y, Li S, Lin JD 2010 Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid. Cell Metab 12:411-419
23. Linke A, Sonnabend M, Fasshauer M, Höllriegel R, Schuler G, Niebauer J, Stumvoll M, Blüher M 2009 Effects of extended-release niacin on lipid profile and adipocyte biology in patients with impaired glucose tolerance. Atherosclerosis 205:207-213
24. Yang J, Zhao SP, Li J, Dong SZ 2008 Effect of niacin on adipocyte leptin in hypercholesterolemic rabbits. Cardiovasc Pathol 17:219-225
25. Worm D, Vinten J, Vaag A, Henriksen JE, Beck-Nielsen H 2000 The nicotinic acid analogue acipimox increases plasma leptin and decreases free fatty acids in type 2 diabetic patients. Eur J Endocrinol 143:389-395
26. Westphal S, Borucki K, Taneva E, Makarova R, Luley C 2007 Extended-release niacin raises adiponectin and leptin. Atherosclerosis 193:361-365 (Pubitemid 47058098)
27. Plaisance EP, Grandjean PW, Brunson BL, Judd RL 2008 Increased total and high-molecular weight adiponectin after extended-release niacin. Metabolism 57:404-409 (Pubitemid 351178732)
28. Westphal S, Luley C 2008 Preferential increase in high-molecular weight adiponectin after niacin. Atherosclerosis 198:179-183 (Pubitemid 351406367)
29. Holmes AG, Watt MJ, Febbraio MA 2004 Suppressing lipolysis increases interleukin-6 at rest and during prolonged moderate-intensity exercise in humans. J Appl Physiol 97:689-696 (Pubitemid 38963143)
30. Watt MJ, Holmes AG, Steinberg GR, Mesa JL, Kemp BE, Febbraio MA 2004 Reduced plasma FFA availability increases net triacylglycerol degradation, but not GPAT or HSL activity, in human skeletal muscle. Am J Physiol Endocrinol Metab 287:E120-E127 (Pubitemid 38856291)
31. Digby JE, McNeill E, Dyar OJ, Lam V, Greaves DR, Choudhury RP 2010 Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 209:89-95
32. Tavintharan S, Lim SC, Sum CF 2009 Effects of niacin on cell adhesion and early atherogenesis: biochemical and functional findings in endothelial cells. Basic Clin Pharmacol Toxicol 104:206-210
33. Tavintharan S, Woon K, Pek LT, Jauhar N, Dong X, Lim SC, Sum CF 2011 Niacin results in reduced monocyte adhesion in patients with type 2 diabetes mellitus. Atherosclerosis 215:176-179
34. Wu ZH, Zhao SP 2009 Niacin promotes cholesterol efflux through stimulation of the PPARγ-LXRα-ABCA1 pathway in 3T3-L1 adipocytes. Pharmacology 84:282-287
35. Siripurkpong P, Na-Bangchang K 2009 Effects of niacin and chromium on the expression of ATP-binding cassette transporter A1 and apolipoprotein A-1 genes in HepG2 cells. J Nutr Biochem 20:261-268
36. Rubic T, Trottmann M, Lorenz RL 2004 Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 67:411-419 (Pubitemid 38236129)
37. Knowles HJ, te Poele RH, Te Poole R, Workman P, Harris AL 2006 Niacin induces PPARγ expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem Pharmacol 71:646-656 (Pubitemid 43121998)
38. Li X, Millar JS, Brownell N, Briand F, Rader DJ 2010 Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes. Biochem Pharmacol 80:1450-1457
39. Gloerich M, Bos JL 2010 Epac: defining a new mechanism for cAMP action. Annu Rev Pharmacol Toxicol 50:355-375
40. Grimaldi PA 2007 Peroxisome proliferator-activated receptors as sensors of fatty acids and derivatives. Cell Mol Life Sci 64:2459-2464 (Pubitemid 350035619)
41. Nakamura MT, Cheon Y, Li Y, Nara TY 2004 Mechanisms of regulation of gene expression by fatty acids. Lipids 39:1077-1083 (Pubitemid 40129050)
42. Lin J, Tarr PT, Yang R, Rhee J, Puigserver P, Newgard CB, Spiegelman BM 2003 PGC-1β in the regulation of hepatic glucose and energy metabolism. J Biol Chem 278:30843-30848 (Pubitemid 36994593)
43. Nisoli E, Vettor R, Tonello C, Macor C, Federspil G, Carruba MO 1999 Nutrient channelling-regulated peroxisome proliferator-activated receptor-γ-2 (PPARγ-2) and leptin gene expression in human subcutaneous fat. Diabetologia 42:495-497 (Pubitemid 29148411)
44. Samec S, Seydoux J, Dulloo AG 1999 Skeletal muscle UCP3 and UCP2 gene expression in response to inhibition of free fatty acid flux through mitochondrial β-oxidation. Pflugers Arch 438:452-457 (Pubitemid 29419898)
45. Capurso A 1991 Drugs affecting triglycerides. Cardiology 78:218-225
46. O'Brien RM, Streeper RS, Ayala JE, Stadelmaier BT, Hornbuckle LA 2001 Insulin-regulated gene expression. Biochem Soc Trans 29:552-558 (Pubitemid 32783656)
47. Quabbe HJ, Luyckx AS, L'Age M, Schwarz C 1983 Growth hormone, cortisol, and glucagon concentrations during plasma free fatty acid depression: different effects of nicotinic acid and an adenosine derivative(BM11.189). J Clin Endocrinol Metab 57:410-414 (Pubitemid 13032499)
48. O'Neill M, Watt MJ, Heigenhauser GJ, Spriet LL 2004 Effects of reduced free fatty acid availability on hormone-sensitive lipase activity in human skeletal muscle during aerobic exercise. J Appl Physiol 97:1938-1945 (Pubitemid 39426014)
49. Pereira JN 1967 The plasma free fatty acid rebound induced by nicotinic acid. J Lipid Res 8:239-244
50. Tran H, Brunet A, Griffith EC, Greenberg ME 2003 The many forks in FOXO's road. Sci STKE 2003:RE5.
51. Lam EW, Francis RE, Petkovic M 2006 FOXO transcription factors: key regulators of cell fate. Biochem Soc Trans 34:722-726 (Pubitemid 44796405)
52. Porstmann T, Griffiths B, Chung YL, Delpuech O, Griffiths JR, Downward J, Schulze A 2005 PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24:6465-6481 (Pubitemid 41486630)
53. Wang W, Basinger A, Neese RA, Christiansen M, Hellerstein MK 2000 Effects of nicotinic acid on fatty acid kinetics, fuel selection, and pathways of glucose production in women. Am J Physiol Endocrinol Metab 279:E50-E59 (Pubitemid 30609944)
54. Dixon JL, Ginsberg HN 1993 Regulation of hepatic secretion of apolipoprotein B-containing lipoproteins: information obtained from cultured liver cells. J Lipid Res 34:167-179 (Pubitemid 23067522)
55. Owen MR, Corstorphine CC, Zammit VA 1997 Overt and latent activities of diacylglycerol acytransferase in rat liver microsomes: possible roles in very-low-density lipoprotein triacylglycerol secretion. Biochem J 323:17-21 (Pubitemid 27153869)
56. Yu XX, Murray SF, Pandey SK, Booten SL, Bao D, Song XZ, Kelly S, Chen S, McKay R, Monia BP, Bhanot S 2005 Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice. Hepatology 42:362-371 (Pubitemid 41061089)
57. Liu Y, Millar JS, Cromley DA, Graham M, Crooke R, Billheimer JT, Rader DJ 2008 Knockdown of acyl-CoA:diacylglycerol acyltransferase 2 with antisense oligonucleotide reduces VLDLTGand ApoB secretion in mice. Biochim Biophys Acta 1781:97-104
58. Ganji SH, Tavintharan S, Zhu D, Xing Y, Kamanna VS, Kashyap ML 2004 Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 45:1835-1845 (Pubitemid 40990875)
59. Jin FY, Kamanna VS, Kashyap ML 1999 Niacin accelerates intra-cellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol 19:1051-1059 (Pubitemid 29177355)
60. Hernandez M, Wright SD, Cai TQ 2007 Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem Biophys Res Commun 355:1075-1080 (Pubitemid 46389506)
61. van der Hoorn JW, De Haan W, Berbée JF, Havekes LM, Jukema JW, Rensen PC, Princen HM 2008 Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE* 3Leiden.CETP mice. Arterioscler Thromb Vasc Biol 28:2016-2022
62. Inazu A, Brown ML, Hesler CB, Agellon LB, Koizumi J, Takata K, Maruhama Y, Mabuchi H, Tall AR 1990 Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 323:1234-1238 (Pubitemid 20366528)
63. Zhang LH, Kamanna VS, Zhang MC, Kashyap ML 2008 Niacin inhibits surface expression of ATP synthase β chain in HepG2 cells: implications for raising HDL. J Lipid Res 49:1195-1201
64. Rasouli N, Hale T, Kahn SE, Spencer HJ, Elbein SC 2005 Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic β-cell function in nondiabetic individuals. J Clin Endocrinol Metab 90:5825-5833 (Pubitemid 41415499)
65. Worm D, Henriksen JE, Vaag A, Thye-Rønn P, Melander A, Beck- Nielsen H 1994 Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period. J Clin Endocrinol Metab 78:717-721 (Pubitemid 24083317)
66. Oh YT, Oh KS, Choi YM, Jokiaho A, Donovan C, Choi S, Kang I, Youn JH 2011 Continuous 24-h nicotinic acid infusion in rats causes FFA rebound and insulin resistance by altering gene expression and basal lipolysis in adipose tissue. Am J Physiol Endocrinol Metab 300:E1012-E1021
67. Tansey JT, Sztalryd C, Gruia-Gray J, Roush DL, Zee JV, Gavrilova O, Reitman ML, Deng CX, Li C, Kimmel AR, Londos C 2001 Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA 98:6494-6499 (Pubitemid 32488265)
68. Ginsberg HN 2006 Niacin in the metabolic syndrome: more risk than benefit? Nat Clin Pract Endocrinol Metab 2:300-301 (Pubitemid 43885891)
69. Rosenson RS 2007 Measure for measure - sugar or fats? Reconciling cardiovascular and diabetes risk with niacin therapy. Nat Clin Pract Endocrinol Metab 3:72-73 (Pubitemid 46146955)
70. Bergman RN, Ader M 2000 Free fatty acids and pathogenesis of type 2 diabetes mellitus. Trends Endocrinol Metab 11:351-356
71. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, Shulman GI 1996 Mechanism of free fatty acid-induced insulin resistance in humans. J Clin Invest 97:2859-2865 (Pubitemid 26197099)
72. Kim JK, Wi JK, Youn JH 1996 Metabolic impairment precedes insulin resistance in skeletal muscle during high-fat feeding in rats. Diabetes 45:651-658 (Pubitemid 26140550)
73. Santomauro AT, Boden G, Silva ME, Rocha DM, Santos RF, Ursich MJ, Strassmann PG, Wajchenberg BL 1999 Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects. Diabetes 48:1836-1841 (Pubitemid 29415205)
74. Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA 2005 Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes 54:3148-3153 (Pubitemid 43334368)
75. Cusi K, Kashyap S, Gastaldelli A, Bajaj M, Cersosimo E 2007 Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes. Am J Physiol Endocrinol Metab 292:E1775-E1781 (Pubitemid 47084713)
76. Majer M, Popov KM, Harris RA, Bogardus C, Prochazka M 1998 Insulin downregulates pyruvate dehydrogenase kinase (PDK) mRNA: potential mechanism contributing to increased lipid oxidation in insulin-resistant subjects. Mol Genet Metab 65:181-186 (Pubitemid 28507139)
77. Altomonte J, Richter A, Harbaran S, Suriawinata J, Nakae J, Thung SN, Meseck M, Accili D, Dong H 2003 Inhibition of Foxo1 function is associated with improved fasting glycemia in diabetic mice. Am J Physiol Endocrinol Metab 285:E718-E728 (Pubitemid 37176422)
78. Daitoku H, Yamagata K, Matsuzaki H, Hatta M, Fukamizu A 2003 Regulation of PGC-1 promoter activity by protein kinase B and the forkhead transcription factor FKHR. Diabetes 52:642-649 (Pubitemid 36323569)